SCHEMBL6608099

SCHEMBL6608099

CCC(C)(C)Oc1[c]cccc1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19405556 0.85
SCHEMBL5387580 0.83 TAAR1 (0.35)
SCHEMBL294588 0.83
SCHEMBL3304649 0.83
SCHEMBL49983 0.79 KIF11 (0.31)
SCHEMBL11144531 0.78
SCHEMBL677247 0.78 ALDH1A1 (0.33) ALDH1A1TSHRTDP1
SCHEMBL9001777 0.77
SCHEMBL10685113 0.77
SCHEMBL9528097 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107004906-B Magnesium-containing electrolyte 富士胶片和光纯药株式会社 2020-04-21 CN disclosed
US-10367231-B2 Magnesium-containing electrolytic solution FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2019-07-30 US disclosed
EP-3226340-B1 MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2018-11-07 EP disclosed
US-20170331154-A1 MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2017-11-16 US disclosed
EP-3226340-A1 MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION Wako Pure Chemical Industries, Ltd. (JP) 2017-10-04 EP disclosed
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-30 US disclosed
EP-1423386-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-02 EP disclosed
WO-2003022842-A1 THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10367231-B2 Magnesium-containing electrolytic solution CA1, CA3, CA2 ALDH1A1 1285/4885TSHR 3749/4885TDP1 2049/4885
US-20040266826-A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors TNF, MMP9, MMP1 ALDH1A1 440/4885TSHR 2444/4885TDP1 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.